On July 25, 2024 Nanjing RegeneCore Biotech reported the RT2831 project has officially obtained Investigational New Drug Application (IND) approval by FDA, USA (Press release, Nanjing RegeneCore Biotech, JUL 25, 2024, View Source [SID1234649773]). This is another major breakthrough for the Regenecore team in the field of tumor treatment after autoimmune diseases, and also the second IND approval for nanobody drugs obtained by the Regenecore team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Regenecore will continue to increase research and development investment, promote the RT2831 project to achieve more positive results in clinical research, and bring more blessings to cancer patients. At the same time, We will actively explore more innovative drugs and continue to move forward firmly on the path of "maintaining human health with excellent drugs".